Belgian IBD Research Group [BIRD] Position Statement 2019 on the Use of Adalimumab Biosimilars in Inflammatory Bowel Diseases

Use of biosimilars in inflammatory bowel disease: A position update of the Italian Group for the Study of Inflammatory Bowel Disease (IG-IBD)

(2019) Gionata Fiorino et al.   DIGESTIVE AND LIVER DISEASE

Consensus report: clinical recommendations for the prevention and management of the nocebo effect in biosimilar-treated IBD patients

(2019) Lieven Pouillon et al.   ALIMENTARY PHARMACOLOGY & THERAPEUTICS

Phase III randomized study of the proposed adalimumab biosimilar GP2017 in psoriasis: impact of multiple switches

(2018) A. Blauvelt et al.   BRITISH JOURNAL OF DERMATOLOGY

Switching Reference Medicines to Biosimilars: A Systematic Literature Review of Clinical Outcomes

(2018) Hillel P. Cohen et al.   DRUGS

Preference for a prefilled syringe or an auto-injection device for delivering golimumab in patients with moderate-to-severe ulcerative colitis: a randomized crossover study

(2018) Séverine Vermeire et al.   Patient Preference and Adherence

Switching From Reference Adalimumab to SB5 (Adalimumab Biosimilar) in Patients With Rheumatoid Arthritis

(2018) Michael E. Weinblatt et al.   Arthritis & Rheumatology

Effectiveness and Safety of Reference Infliximab and Biosimilar in Crohn Disease: A French Equivalence Study

(2018) Antoine Meyer et al.   ANNALS OF INTERNAL MEDICINE

The PROSIT-BIO Cohort

(2017) Gionata Fiorino et al.   INFLAMMATORY BOWEL DISEASES

A randomized phase I comparative pharmacokinetic study comparing SB5 with reference adalimumab in healthy volunteers

(2017) D. Shin et al.   JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS

Role of Buffers in Protein Formulations

(2017) Teddy J. Zbacnik et al.   JOURNAL OF PHARMACEUTICAL SCIENCES

Clinical similarity of biosimilar ABP 501 to adalimumab in the treatment of patients with moderate to severe plaque psoriasis: A randomized, double-blind, multicenter, phase III study

(2017) Kim Papp et al.   JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY

Switching from originator infliximab to biosimilar CT-P13 compared with maintained treatment with originator infliximab (NOR-SWITCH): a 52-week, randomised, double-blind, non-inferiority trial

(2017) Kristin K Jørgensen et al.   LANCET

Assessing the Value of Biosimilars: A Review of the Role of Budget Impact Analysis

(2017) Steven Simoens et al.   PHARMACOECONOMICS

Phase III Randomized Study of SB5, an Adalimumab Biosimilar, Versus Reference Adalimumab in Patients With Moderate-to-Severe Rheumatoid Arthritis

(2017) Michael E. Weinblatt et al.   Arthritis & Rheumatology

A randomised, single-blind, single-dose, three-arm, parallel-group study in healthy subjects to demonstrate pharmacokinetic equivalence of ABP 501 and adalimumab

(2016) Primal Kaur et al.   ANNALS OF THE RHEUMATIC DISEASES

Efficacy and safety of switching from reference infliximab to CT-P13 compared with maintenance of CT-P13 in ankylosing spondylitis: 102-week data from the PLANETAS extension study

(2016) Won Park et al.   ANNALS OF THE RHEUMATIC DISEASES

Demonstration of Functional Similarity of Proposed Biosimilar ABP 501 to Adalimumab

(2016) Jyoti Velayudhan et al.   BIODRUGS

Assessing Analytical Similarity of Proposed Amgen Biosimilar ABP 501 to Adalimumab

(2016) Jennifer Liu et al.   BIODRUGS

Comparison of the pharmacokinetics, safety, and immunogenicity of MSB11022, a biosimilar of adalimumab, with Humira®in healthy subjects

(2016) Elizabeth Hyland et al.   BRITISH JOURNAL OF CLINICAL PHARMACOLOGY

Demonstration of physicochemical and functional similarity between the proposed biosimilar adalimumab MSB11022 and Humira®

(2016) Laurent Magnenat et al.   mAbs

Biosimilars: the science of extrapolation

(2014) M. Weise et al.   BLOOD

Biosimilars: what clinicians should know

(2012) M. Weise et al.   BLOOD